Table 2.

Summary of neoantigen reactivities identified in 75 patients with GI cancers

Number (%) of patients with TILs recognizing the following number of neoantigens
CancerNumber of patients screenedNumber (%) of patients with neoantigen-reactive TILsMedian number of nonsynonymous mutationsTotal number of variant transcripts screened/total number of variant transcripts (%)Total number of immunogenic neoantigens (% of variant transcripts screened)Number (%) CD8 reactivitiesNumber (%) CD4 reactivities0123>3
Colorectal5145 (88%)1265,833/7,710 (76%)94 (1.6%)a47 (50%)47 (50%)6 (12%)17 (33%)16 (31%)a7 (14%)5 (10%)a
Bile duct128 (67%)59866/1,901 (46%)12 (1.4%)3 (25%)9 (75%)4 (33%)5 (42%)2 (17%)1 (8%)0 (0%)
Pancreatic75 (71%)56352/407 (86%)8 (2.3%)3 (38%)5 (63%)2 (29%)2 (29%)3 (43%)0 (0%)0 (0%)
Stomach32 (67%)148378/445 (85%)6 (1.6%)3 (50%)3 (50%)1 (33%)0 (0%)1 (33%)0 (0%)1 (33%)
Esophageal22 (100%)119225/252 (89%)4 (1.8%)1 (25%)3 (75%)0 (0%)1 (50%)0 (0%)1 (50%)0 (0%)
Totals or medians (GI)7562 (83%)1147,654/10,715 (71%)124 (1.6%)a57 (46%)67 (54%)13 (17%)24 (32%)23 (31%)9 (12%)6 (8%)
  • aOne patient (4259) had CD8+ and CD4+ T cells that recognized mutated TP53 epitopes that were counted as 2 separate antigens.

  • One patient (4241) had CD8+ and CD4+ T cells that recognized mutated CCAR2 and MED14 epitopes, both of which were counted as 2 separate antigens.